Table V.
Outcomes of the simulated clinical trial on haemoglobin optimisation: 10,000 patients were randomly assigned to the haemoglobin optimisation or the control (no optimisation) arms.
| Control arm | Optimisation arm | ||
|---|---|---|---|
| Patients transfused | 6,595 | 2,212 | |
| RBC units transfused | 13,336 | 4,341 | |
| Cost* | - | € 3,641,421 | |
| Laboratory | - | € 210,000 | (6%) |
| Hospital outpatient clinic | - | € 1,966,500 | (54%) |
| Ferric carboxymaltose | - | € 1,464,921 | (40%) |
| Cost per patient transfused avoided | € 831 | ||
| Cost per RBC unit avoided | € 405 |
*
Incremental cost as compared with the control arm; RBC: red blood cell.